Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 4, 2011, Pages 421-429

  Anai, Satoshi ^a   Sakamoto, Noboru ^b   Sakai, Yoshihisa ^b   Tanaka, Motoyoshi ^c   Porvasnik, Stacy ^b   Urbanek, Cydney ^b   Cao, Wengang ^b   Goodison, Steve ^d   Rosser, Charles J ^b  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF FLORIDA   (United States)

^c KINKI UNIVERSITY   (Japan)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bcl 2; Therapeutic; Vascular endothelial growth factor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BEVACIZUMAB; INTERLEUKIN 8; PROTEIN BCL 2; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SIZE; CARCINOGENICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOOD VESSELS; CELL LINE; CELL LINE, TUMOR; DNA, ANTISENSE; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959879734     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.04.009     Document Type: Article

References (34)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Concato J., Jain D., Li W.W., et al. Molecular markers and mortality in prostate cancer. BJU Int 2007, 100:1259-1263.
3. Matsushima H., Kitamura T., Goto T., et al. Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 1997, 158:2278-2283.
4. Lucken-Ardjomande S., Martinou J.C. Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane. C R Biol 2005, 328:616-631.
5. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 2005, 333:336-343.
6. Anai S., Goodison S., Shiverick K., et al. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization in the human PC3 prostate tumor model. Mol Cancer Ther 2007, 6:101-111.
7. Iervolino A., Trisciuoglio D., Ribatti D., et al. Bcl-2 over expression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002, 16:1453-1455.
8. Fernandez A., Udagawa T., Schwesinger C., et al. Angiogenic potential of prostate carcinoma cells over expressing bcl-2. J Natl Cancer Inst 2002, 93:208-213.
9. Anai S., Goodison S., Shiverick K., et al. A combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Human Gene Ther 2006, 16:1063-1073.
10. Anai S., Brown B.D., Nakamura K., et al. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide. Int J Radiat Oncol Biol Phys 2007, 68:1161-1168.
11. Zupi G., Scarsella M., Semple S.C., et al. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: Relevance of the administration sequence. Clin Cancer Res 2005, 11:1990-1998.
12. Xiao D., Singh S.V. z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol Cancer Ther 2008, 7:171-180.
13. Rosser C.J., Reyes A.O., Vakar-Lopez F., et al. p53 and Bcl-2 are over expressed in localized radio-recurrent carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2003, 56:1-6.
14. Rosser C.J., Tanaka M., Pisters L.L., et al. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 2004, 11:273-279.
15. Sakai Y, Goodison S, Kusmartev S, et al. Bcl-2 modulates angiogenesis and lymphangiogenesis in PC-3 xenografts. Proceedings of the Annual Meeting of the American Association of Cancer Research. Los Angeles, (CA), April 14-18, 2007.
16. Nor J.E., Christensen J., Mooney D.J., et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999, 154:375-384.
17. Sakai Y, Goodison S, Cao W, et al. VEGF induces expression of Bcl-2 and multiple signaling factors in microvascular endothelial cells. Proceedings of the Annual Meeting of the American Association of Cancer Research. Los Angeles, (CA), April 14-18, 2007.
18. Fidler I.J. Critical factors in the biology of human cancer metastasis: Twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res 1990, 50:6130-6138.
19. Fidler I.J. Modulation of the organ microenvironment for the treatment of cancer metastasis (commentary). J Natl Cancer Inst 1995, 87:1588-1592.
20. Greene G.F., Kitadai Y., Pettaway C.A., et al. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997, 150:1571-1582.
21. Balbay M.D., Pettaway C.A., Kuniyasu H., et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice over expresses vascular endothelial growth factor. Clin Cancer Res 1999, 5:783-789.
22. Auerbach W., Auerbach R. Angiogenesis inhibition: A review. Pharmacol Ther 1994, 63:265-311.
23. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447.
24. Senger D.R., Galli S.J., Dvorak A.M., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
25. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
26. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-858.
27. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
28. Ferrara N., Heinsohn H., Walder C.E., et al. The regulation of blood vessel growth by vascular endothelial growth factor. Ann NY Acad Sci 1995, 752:246-256.
29. Zeitlin B.D., Joo E., Dong Z., et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006, 66:8698-8706.
30. Song J.H., Kandasamy K., Kraft A.S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 2008, 283:25003-25013.
31. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52:6940-6944.
32. McDonnell T.J., Chari N.S., Cho-Vega J.H., et al. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics 2008, 1:1.
33. Rosser C.J., Reyes A.O., Vakar-Lopez F., et al. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 2003, 56:1-6.
34. Stackhouse G.B., Sesterhenn I.A., Bauer J.J., et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999, 162:2040-2045.